Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market and supply shortages of the drug Adderall. He speaks to "Bloomberg Open ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

Now, the Florida-based drugmaker has parried another Firdapse challenger in Teva Pharmaceuticals, which had hoped to market a generic version of the Lambert-Eaton myasthenic syndrome (LEMS ...

Teva cannot market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific conditions arise. Ongoing Firdapse patent litigation continues against Hetero and Lupin ...

Catalyst Pharmaceuticals, Inc. has reached a Settlement Agreement with Teva Pharmaceuticals regarding patent litigation over the generic version of FIRDAPSE® (amifampridine) 10 mg tablets.

(MENAFN- GlobeNewsWire - Nasdaq) As Part of the Settlement, Teva Receives a License to market Generic FIRDAPSE Beginning in February 2035 CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE ...

This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE ® ...

UBS analyst Ashwani Verma raised the firm’s price target on Teva (TEVA) to $28 from $26 and keeps a Buy rating on the shares. After Phase 2 duvakitug data surpassed expectations, the firm ...

This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic ...